New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
10:55 EDTAETI, AETI, CATS, CATS, NSSC, NSSC, MVIS, MVIS, DARA, DARA, OXGN, OXGN, WYY, WYY, VICL, VICL, BJRI, BJRI, INSV, INSVRoth Capital to hold a conference
26th Annual Growth Stock Conference is being held in Dana Point, California on March 9-12 with webcasted company presentations to begin on March 12 at 11 am; not all company presentations may be webcasted. Webcast Link
News For AETI;BJRI;VICL;WYY;OXGN;DARA;MVIS;NSSC;CATS;INSV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
07:48 EDTWYYWidePoint still sees Q3 revenue $14.3M-$14.7M , consensus $14.03M
07:47 EDTWYYWidePoint receives new commercial enterprise awards for $3.4M in Q3
Subscribe for More Information
October 9, 2014
11:42 EDTBJRIRuby Tuesday surges after Q1 profit beats estimates
Subscribe for More Information
October 8, 2014
07:47 EDTWYYWidePoint receives four new federal contract awards for $2.7M
WidePoint has received a contract award from a new federal government agency customer and three new additional Task Orders under a recently awarded Federal Government Blanket Purchase Agreement. The new awards bring to WidePoint an additional agency under yet another Federal Department. The awards have a period of performance of one year and total approximately $2.7M with the potential for the customers to choose extending the awards.
06:33 EDTVICLVical granted six U.S. patents for HSV-2 vaccines
Vical has been issued six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2, containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant. The intellectual property is jointly owned by the University of Washington and Vical.
October 7, 2014
16:03 EDTOXGNOXiGENE announces first patient enrolled in phase 1b/2 study of Fosbretabulin
OXiGENE announced that the first patient has been enrolled in a phase 1b/2 clinical study that will evaluate fosbretabulin in combination with Votrient in patients with recurrent ovarian cancer. The randomized, controlled clinical study consists of a phase 1b dose escalation portion with the combination of fosbretabulin and pazopanib and a phase 2 portion comparing fosbretabulin and pazopanib versus pazopanib alone. The study is estimated to enroll up to 128 patients at sites in the United Kingdom. The primary endpoint is progression-free survival, and secondary endpoints include safety, overall survival, objective response rate and relevant biomarkers.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use